Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$153.92
-1.0%
$149.43
$111.09
$169.37
$9.38B0.54478,466 shs255,010 shs
Moderna, Inc. stock logo
MRNA
Moderna
$26.24
-2.1%
$31.25
$23.15
$170.47
$10.14B2.237.22 million shs7.02 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$46.95
+4.3%
$44.37
$24.22
$60.60
$2.88B2.3839,427 shs2.15 million shs
Qiagen stock logo
QGEN
Qiagen
$41.52
-1.9%
$39.70
$37.63
$49.30
$9.23B0.621.13 million shs2.40 million shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
+2.99%+10.96%+1.65%+18.19%+6.48%
Moderna, Inc. stock logo
MRNA
Moderna
+2.29%+4.52%-22.59%-22.23%-74.51%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
+5.65%+4.21%-17.80%+22.80%+66.53%
Qiagen stock logo
QGEN
Qiagen
+0.77%+4.89%+7.09%-4.48%+8.28%
Remove Ads
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.3142 of 5 stars
3.52.00.00.03.11.70.6
Moderna, Inc. stock logo
MRNA
Moderna
4.259 of 5 stars
4.01.00.04.62.22.51.3
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.8055 of 5 stars
4.53.00.00.03.02.51.3
Qiagen stock logo
QGEN
Qiagen
3.483 of 5 stars
2.13.00.04.52.31.71.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
2.93
Moderate Buy$204.6432.95% Upside
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$58.70123.70% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3.00
Buy$65.4439.39% Upside
Qiagen stock logo
QGEN
Qiagen
2.27
Hold$47.7114.89% Upside

Current Analyst Ratings Breakdown

Latest PTGX, MRNA, ASND, and QGEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$80.00 ➝ $80.00
4/9/2025
Moderna, Inc. stock logo
MRNA
Moderna
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$39.00 ➝ $32.00
4/4/2025
Qiagen stock logo
QGEN
Qiagen
Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
3/28/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$70.00 ➝ $70.00
3/21/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$40.00 ➝ $33.00
3/18/2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$168.00 ➝ $200.00
3/13/2025
Moderna, Inc. stock logo
MRNA
Moderna
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageNeutral$40.00
3/11/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$70.00
3/11/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$60.00 ➝ $76.00
3/11/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$62.00 ➝ $72.00
3/10/2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$54.00 ➝ $54.00
(Data available from 4/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
$363.64M25.81N/AN/A($1.88) per share-81.87
Moderna, Inc. stock logo
MRNA
Moderna
$3.20B3.17N/AN/A$28.33 per share0.93
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$434.43M6.63N/AN/A$5.84 per share8.04
Qiagen stock logo
QGEN
Qiagen
$1.98B4.67$3.46 per share12.01$16.08 per share2.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$409.12M-$7.10N/A641.33N/A-104.54%N/A-39.23%5/1/2025 (Estimated)
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$9.28N/AN/AN/A-110.04%-28.74%-21.83%5/1/2025 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$78.96M$4.2017.65N/AN/A52.76%34.68%30.98%5/6/2025 (Estimated)
Qiagen stock logo
QGEN
Qiagen
$83.59M$0.36115.6216.882.394.23%13.92%8.40%5/7/2025 (Estimated)

Latest PTGX, MRNA, ASND, and QGEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2025Q1 2025
Qiagen stock logo
QGEN
Qiagen
$0.49N/AN/AN/A$465.66 millionN/A
5/6/2025Q1 2025
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.50N/AN/AN/A$30.44 millionN/A
5/1/2025Q1 2025
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.56N/AN/AN/A$98.56 millionN/A
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.90N/AN/AN/A$130.35 millionN/A
2/21/2025Q4 2024
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.09$1.98+$2.07$1.98$56.65 million$170.64 million
2/12/2025Q4 2024
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
-$1.32-$0.68+$0.64-$0.68$115.06 millionN/A
2/5/2025Q4 2024
Qiagen stock logo
QGEN
Qiagen
$0.60$0.61+$0.01$0.39$518.54 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/AN/AN/AN/AN/A
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A
Qiagen stock logo
QGEN
Qiagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
1.17
0.84
Moderna, Inc. stock logo
MRNA
Moderna
N/A
3.67
3.62
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
10.69
10.70
Qiagen stock logo
QGEN
Qiagen
0.38
3.61
3.09

Institutional Ownership

CompanyInstitutional Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
N/A
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%
Qiagen stock logo
QGEN
Qiagen
70.00%

Insider Ownership

CompanyInsider Ownership
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
40.00%
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
5.40%
Qiagen stock logo
QGEN
Qiagen
9.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
1,01760.97 million36.41 millionOptionable
Moderna, Inc. stock logo
MRNA
Moderna
3,900386.62 million324.40 millionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12061.38 million56.38 millionOptionable
Qiagen stock logo
QGEN
Qiagen
6,030222.29 million201.89 millionOptionable

Recent News About These Companies

Qiagen stock logo
Qiagen (NYSE:QGEN) Issues FY25 Earnings Guidance
Qiagen stock logo
Qiagen (NYSE:QGEN) Issues Q1 Earnings Guidance
Jefferies Remains a Buy on Qiagen (QGEN)
Qiagen Shares Rise After Guidance Lift
Qiagen gains after guidance raise
TD Cowen Keeps Their Hold Rating on Qiagen (QGEN)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Ascendis Pharma A/S stock logo

Ascendis Pharma A/S NASDAQ:ASND

$153.92 -1.58 (-1.02%)
Closing price 04:00 PM Eastern
Extended Trading
$154.62 +0.70 (+0.45%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Moderna stock logo

Moderna NASDAQ:MRNA

$26.24 -0.56 (-2.09%)
Closing price 04:00 PM Eastern
Extended Trading
$25.82 -0.41 (-1.58%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$46.95 +1.92 (+4.26%)
Closing price 04:00 PM Eastern
Extended Trading
$46.72 -0.23 (-0.50%)
As of 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Qiagen stock logo

Qiagen NYSE:QGEN

$41.52 -0.80 (-1.88%)
Closing price 03:59 PM Eastern
Extended Trading
$41.52 +0.00 (+0.00%)
As of 05:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.